Eli Lilly Receives Breakthrough Therapy Designation from the FDA for Sofetabart Mipitecan for the Treatment of Platinum-Resistant Ovarian Cancer. Analysts give the stock a “buy” rating.
Eli Lilly has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the cancer treatment Sofetabart Mipitecan for the treatment of certain patients with ovarian cancer. The pharmaceutical company announced on Tuesday that the Sofetabart designation includes mipitecan for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have previously been treated with bevacizumab and mirvetuximab soravtansine, if eligible.
It aims to accelerate the development and testing of a drug for serious diseases when preliminary clinical evidence shows the drug could provide a significant improvement over available therapies.
wallstreetONLINE Redaktion
Show more
Show more
